- Home
- AIRI vs QNRX Comparison
AIRI vs QNRX Comparison
Compare AIRI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRI | QNRX |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 14.5M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AIRI | QNRX |
|---|---|---|
| Price | $3.14 | $6.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.1K | ★ 27.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $5.20 |
| 52 Week High | $4.17 | $41.80 |
Technical Indicators
Market Signals| Indicator | AIRI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 46.51 |
| Support Level | $2.82 | $5.47 |
| Resistance Level | $3.15 | $6.98 |
| Average True Range (ATR) | 0.08 | 0.52 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 52.02 | 53.93 |
Price Performance
Historical ComparisonAbout AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.